14.04.2016 16:32:00

Moody's: Strength of Allergan's credit profile will depend on use of cash from divestiture

New York, April 14, 2016 -- Allergan's use of cash following the divestiture of its generics business to Teva Pharmaceuticals would be positive for creditors if the company pursues tuck-in acquisitions of late-stage pipeline products, but negative if it pursues a megadeal funded heavily with debt.

Vollständigen Artikel bei Moodys lesen